Praxis Precision Medicines (PRAX) stock gain as the company speed up R&D plans for its seizure drug relutrigine following ...
Praxis Precision Medicines (NASDAQ:PRAX) added ~134% in the premarket on Thursday after the Boston-based biotech announced that its experimental therapy ulixacaltamide succeeded in two late-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback